Therapeutic areas

Our therapeutic expertise

Our experience in managing complex hospital-based studies spans multiple therapeutic areas and specific indications across Phase I-III studies, with a core therapeutic focus on Oncology and Rare Disease.

Our combined experience in clinical pharmacology and clinical development also includes Respiratory, Anti-Infectives & Vaccines, Dermatology, Gastro-Intestinal, Critical Care Medicine, Medical Devices, Hepatic and Biliary, and Pulmonary. 

It is this wide therapeutic experience working in various indications which enables us to bring insight to your clinical development and manage the most challenging studies.

Extensive therapeutic expertise

We offer expertise across a broad range of therapeutic areas in clinical research, enabling efficient development from beginning to end. With specialist knowledge and experience in multiple areas, we ensure your drug development process transitions seamlessly across all therapeutic specialties.

Whether your project requires a full development programme or specialist service, we help get your drug to market faster.

COVID-19 Clinical Trials

Our expertise in managing over 120 hospital-based critical care, infectious diseases and respiratory studies provides the experience you can lean on to conduct clinical trials for COVID-19.  

We have more than 45 years of expertise from First-In-Human studies through to Phase IV delivered by tight-knit teams, motivated and forward-thinking. 

We will prioritise any COVID-19 RFP for input and review allowing important research to move rapidly at this important time. We have a streamlined contracting process in place and can start work on projects with a Letter of Intent – given the circumstances our agility enables us to remove hurdles and progress clinical research that will improve all our lives.

How our scientific affairs group adds value – and reduces risk

Dr Simon Hutchings, Director of Scientific Affairs

Discover how the experience and expertise of our team enables us to reduce risk – including regulatory risk – and focus on designing studies to gain maximum valuable data.

Let’s collaborate

If you think we could be right for you, get in touch.

Submit an RFI/RFP